Brolucizumab in recalcitrant neovascular age-related macular degeneration –real-world data in Chinese population

by Chang-Chi Weng, Sheng-Chu Chi, Tai-Chi Lin, Yi-Ming Huang, Yu-Bai Chou, De-Kuang Hwang, Shih-Jen Chen This retrospective study aimed to determine the short-term efficacy and safety of brolucizumab treatment for recalcitrant neovascular age-related macular degeneration (nAMD) in a real-world setting in Taiwan. Recalcitrant nAMD patients who were treated with brolucizumab from November 2021 to Augus t 2022 at Taipei Veterans General Hospital were included. Patients were followed for 3 months after switching to brolucizumab. The primary outcomes were changes in mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to the third month. The secondary outcomes in cluded the incidence of intraocular inflammation (IOI), proportion of patients with subretinal and intraretinal fluid (SRF and IRF), and change in pigment epithelial detachment (PED) height from baseline to the third month. The significance level was considered as p
Source: PLoS One - Category: Biomedical Science Authors: Source Type: research